Status:
COMPLETED
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
Lead Sponsor:
Vistakon Pharmaceuticals
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
10+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allerg...
Eligibility Criteria
Inclusion
- history of ocular allergies and a positive skin test reaction to cat hair, cat dander, grasses, ragweed, and/or trees within the past 24 months; calculated best-corrected visual acuity of 0.6 logMar or better in each eye; positive bilateral conjunctival allergy challenge reaction
- \-
Exclusion
- narrow angle glaucoma, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium or diagnosis of dry eye; ocular surgical intervention within 3 months; history of refractive surgery within 6 months; known history of retinal detachment, diabetic retinopathy, or progressive retinal disease; presence of active ocular infection positive history of an ocular herpetic infection; preauricular lymphadenopath; manifest signs or symptoms of clinically active allergic conjunctivitis
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00244543
Start Date
October 1 2005
Last Update
September 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
North Andover, Massachusetts, United States